DORMICUM 15mg price in UAE

Overview

Welcome to Dwaey, specifically on DORMICUM 15mg Tablets page.
This medicine contains an important and useful components, as it consists of Midazolam.
DORMICUM 15mg is available in the market in concentration 15mg/Tablet and in the form of Tablets.

CHEPLAPHARMÊ ARZNEIMITTEL GMBH is the producer of DORMICUM 15mg and it is imported from GERMANY, The most popular alternatives of DORMICUM 15mg are listed downward .

Mode Of Action

Midazolam is a short-acting benzodiazepine. It exerts sedative and hypnotic, muscle relaxant, anxiolytic and anticonvulsant actions. While the probable anxiolytic action might be as a result of the drug's ability to increase glycine inhibitory neurotransmitter level, the hypnotic/anaesthetic action may be due to the occupation of the benzodiazepine and GABA receptors leading to membrane hyperpolarisation and neuronal inhibition, and further interfering with the re-uptake of GABA at the synapses.

Indication

Insomnia
Sedation
Induction of anesthesia

Precaution

Patients w/ heart failure, impaired gag reflex, resp disease, history of alcohol or drug abuse. Patient at risk of falls. Hepatic and renal impairment. Childn, elderly and debilitated patient. Pregnancy and lactation. Avoid abrupt withdrawal after prolonged use. Avoid rapid inj in neonates. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor resp and CV status, BP. Lactation: Distributed in breast milk, use caution

Side Effects

>10% Decreased respiratory rate (23%)
Apnea (15%) 1-10% Drowsiness (1-5%)
Seizure-like activity (1%)
Nausea/vomiting (3%)
Cough (1%)
Pain at injection site (4-5%) Frequency Not Defined Headache
Sedation
Hiccoughs
Delirium
Euphoria Pediatric Desaturation
Hypotension
Seizurelike activity
Nystagmus
Paradoxical reactions
Hiccoughs
Apnea

Contra indication

Severe resp failure or acute resp depression, acute narrow-angle glaucoma, myasthenia gravis, sleep apnoea syndrome; severe hepatic impairment (oral). Concomitant use w/ potent CYP3A4 inhibitors.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Interaction

Increased CNS depression with alcohol, opioids, barbiturates, other sedatives and anaesthetics. Increased respiratory depression with opiates, phenobarbital, other benzodiazepines. Plasma concentrations increased by CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, diltiazem, verapamil, ketoconazole and itraconazole, antiretroviral agents, quinupristin with dalfopristin. Midazolam concentration decreased by phenytoin, carbamazepine, phenobarbital, rifampicin. Halothane, thiopental requirements may be reduced during concurrent use.